版本:
中国

BRIEF-FDA approves 6-month primary end point for the Lutonix

Sept 19 C. R. Bard, Inc

* Approves 6 Primary efficacy end point in clinical trial is a composite of limb salvage and primary patency at 6 months

* Month primary end point for the Lutonix below-the-knee drug coated balloon

* Primary safety end point in clinical trial is freedom from major adverse limb event or postoperative death at 30 days Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐